Description
Review of recent evidence on recently endorsed procedures and adjuvant management with anti-obesity medications from the worldwide experience standpoint, including the impact and level of evidence of new 2022 ASMBS/IFSO guidelines. The session should be of great interest to clinicians at all levels of experience.
Learning Objectives
- Understand the management options with the use of Anti-Obesity Medicines and Metabolic Bariatric Surgery.
- Review recent Randomized Clinical Trials and implications.
- Learn the level of evidence and impact of the new 2022 ASMBS/IFSO guidelines.
- Learn the effects of obesity treatments in cardiovascular risk reduction.
| 1:30pm |
Results from the IFSO Consensus Conference on Obesity Management Medications and Metabolic/Bariatric Surgery Gerhard Prager, MD |
| 2:00pm |
Long Term Results from RCTs: Sleeve-Pass, SM-BOSS, SleeveBypass Dutch trial Paulina Salminen, MD PhD |
| 2:30pm |
Impact of YOMEGA Trial [5years results] in patient selection for OAGB vs RYGB Helmuth T Billy, MD |
| 3:00pm | Break |
| 3:30pm |
Implications of RCTs on Decision Making Ricardo V Cohen, MD |
| 3:55pm |
Level of Evidence supporting the ASMBS/IFSO 2022 Guidelines Maurizio De Luca, MD PhD |
| 4:20pm |
Uptake of the new guidelines in the US and worldwide Jaime Ponce, MD |
| 4:45pm |
Cardiovascular risk reduction: Semaglutide SELECT trial vs Metabolic Surgery Ali Aminian, MD FACS FASMBS |
| 5:10pm | Adjourn |